miRNA profiling of NurOwn®: mesenchymal stem cells secreting neurotrophic factors

Mesenchymal stromal cells (MSC) are multipotent cells capable of differentiating into cells associated with multiple lineages [ 1 ]. MSC are being evaluated like a potential therapy for a wide variety of degenerative and immunological problems [ 2 ]. We have developed a culture-medium based method for inducing MSCs to secrete enhanced levels of multiple neurotrophic factors (NTFs) including glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic aspect (BDNF) vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) [ 3 ]. MSC-NTF cells (NurOwn® ) have been successfully used in clinical trials for amyotrophic lateral sclerosis (ALS) patients [ 4 ]. NTFs are small, normally occurring polypeptides that support the development and success of neurons [ 5 ]. NTFs are potent success factors for embryonic, neonatal, and adult neurons, and also have been evaluated in various neurodegenerative disease clinical trials in the last 25 years [ 6 , 7 ]. MSC-NTF cells that have been induced in order to enhanced secretion of NTFs, offer a novel method for at the same time delivering multiple NTFs to patients with neurodegenerative illnesses such as ALS, while leveraging the potential immunomodulatory therapeutic advantages of MSCs [ 8 ]. Furthermore, a recent study demonstrated possible therapeutic benefits of MSC-NTF cells in an animal model of autism [ 9 ]. ALS (also known as Lou Gehrig’ s disease) is really a rare, relentlessly progressive and...

Read More